Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shenzhen - Delayed Quote CNY

Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ)

Compare
37.00
+1.55
+(4.37%)
At close: April 2 at 3:04:21 PM GMT+8
Loading Chart for 002422.SZ
  • Previous Close 35.45
  • Open 31.67
  • Bid 36.97 x --
  • Ask 36.98 x --
  • Day's Range 35.51 - 38.08
  • 52 Week Range 25.72 - 38.08
  • Volume 46,363,938
  • Avg. Volume 16,957,308
  • Market Cap (intraday) 59.128B
  • Beta (5Y Monthly) 0.05
  • PE Ratio (TTM) 19.58
  • EPS (TTM) 1.89
  • Earnings Date --
  • Forward Dividend & Yield 0.52 (1.47%)
  • Ex-Dividend Date Oct 23, 2024
  • 1y Target Est 43.29

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers infusion products; oral medication and other dosage form; plastic ampoule and powder liquid dual chamber infusion bag; medical devices, such as infusion set, injection syringes, detained needles, nebulizer, and blood sampling; and over-the-counter products. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.

www.kelun.com

19,798

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002422.SZ

View More

Performance Overview: 002422.SZ

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002422.SZ
23.62%
SSE Composite Index (000001.SS)
0.05%

1-Year Return

002422.SZ
28.62%
SSE Composite Index (000001.SS)
8.95%

3-Year Return

002422.SZ
131.13%
SSE Composite Index (000001.SS)
2.05%

5-Year Return

002422.SZ
97.22%
SSE Composite Index (000001.SS)
20.48%

Compare To: 002422.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002422.SZ

View More

Valuation Measures

As of 4/2/2025
  • Market Cap

    59.13B

  • Enterprise Value

    56.83B

  • Trailing P/E

    19.58

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.57

  • Price/Book (mrq)

    2.62

  • Enterprise Value/Revenue

    2.53

  • Enterprise Value/EBITDA

    11.52

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.17%

  • Return on Assets (ttm)

    7.22%

  • Return on Equity (ttm)

    14.14%

  • Revenue (ttm)

    22.5B

  • Net Income Avi to Common (ttm)

    2.96B

  • Diluted EPS (ttm)

    1.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.08B

  • Total Debt/Equity (mrq)

    21.79%

  • Levered Free Cash Flow (ttm)

    1.33B

Research Analysis: 002422.SZ

View More

People Also Watch